Why Moderna Stock Rallied Today
Shares of Moderna (NASDAQ: MRNA) climbed 7.5% on Tuesday after health officials in the U.K. approved the drugmaker's COVID-19 vaccine for children ages 12 to 17.
The Medicines and Healthcare products Regulatory Agency (MHRA) issued a conditional approval for Moderna's vaccine, now called Spikevax, based on clinical trials that showed the drug to be safe and effective in kids 12 years of age and older.
Image source: Getty Images.
Source Fool.com
